Human-Ultracell 1000Mg (750-mg vial) (250-mg syringe)

ANTI-AGING VACCINE

USING SWISS SCIENCE TO COMBAT AGEING

Human Ultracell is the most powerful therapeutic resource available today to renew and regenerate the body, detain the ageing process and prevent degenerative diseases.
It works clinically to achieve three basic results: a powerful effect against ageing, stress and degenerative diseases.

The anti-ageing result manifests itself in the individual’s physical appearance, since it improves the skin, eliminates spots, and detains premature grey hair. With consistent use, each year the patient will look younger than his/her real chronological age.  

Another noteworthy result is the anti-stress effect which enhances the patient’s mood and increases his/her energy and cognitive ability considerably, whilst eliminating physical exhaustion, increasing libido, and improving quality of sleep.

The third major result is that Human Ultracell will progressively boost the immune system so that the body can fend off degenerative and catastrophic diseases, such as:  cancer, Parkinson’s disease, Alzheimer’s disease, arthritis, and cardiovascular diseases.

The clinical experience yielded by this research supports the use thereof in combination with other medications, since its coadjutant and boosting action prove the preventative efficacy of Human Ultracell.

Human Ultracell is an injectable complex of powerful biostimulants which induce the production of human growth hormone (HGH) which, in turn, improves all organ functions in older adults. An increased production of HGH can reverse the deterioration caused by ageing and increase general well-being, through the timely induction and constant increase in the production and secretion of other hormones of vital necessity for keeping the body running as if it were young. We recommend yearly treatments of Human Ultracell as of age 30.

Action: Renews and revitalises.

Proven deep clinical action in

Cell renewal and revitalisation therapy. Second-line treatment for chronic and degenerative diseases. Post-chemo and radiation therapy treatment of cancer patients. 

• Cases of underperformance of endocrine glands.  
• Complete immediate therapeutic effect. Yearly treatment.
• No side effects.
• Safe.
• No drug interactions.

Composition, 1000 mg:
Available in 2 forms, with different formulas. The traditional formula contains opotherapy cell compounds, stem cells and hormone inducers; Human Ultracell Phyto contains germinated phyto cell compounds (Juvenxa). In both cases, the formulas contain concentrations of 750 mg of lyophilised [freeze-dried] powder and 250 mg of solvent liquid in a syringe. The latter represents the second part of the formula, which should be mixed together with the vial at the time of injection, for the total 1000-mg dose of Human Ultracell, in both cases.

What is felt when one uses Human Ultracell and what are its benefits?
The first thing noticed is an increase in energy, until the general organ renewal is completed, in addition to the protection and sense of security one feels when one is vaccinated against contagious and viral diseases, with the main benefit that Human Ultracell shields the user against the risks which ageing and its sequelae imply, maintaining good health and quality of life through cell renewal.

Its main benefits are:

• Increases energy to youthful levels.
  
• Rejuvenates each cell of the body.
  
• Boosts the immune system.
  
• Retards ageing.
  
• Revitalises organs, improving their functions.
  
• Prevents the formation of malignant cells and degenerative diseases.
  
• Boosts cognitive functions (memory, concentration, and state of alertness).
  
• Improves cardiac and pulmonary function.
  
• Revitalises sex life.
  
• Reduces body fat and increases muscle mass by natural induction of human growth hormone
• (HGH)
  
• Generates better tolerance to exercise.
  
• Increases muscle tone and strength.
  
• Increases bone density.
  
• Improves skin elasticity and prevents the formation of wrinkles and spots.
  
• Improves fluid balance.
  
• Regulates the sleep mechanism.

How long before its effects are noted?
Human Ultracell follows the biological route:
From cell to tissue – from tissue to organ – from organ to system.
Its effect is physiologically sustained and begins to be noted as of the first three weeks of treatment.

What side effects and reactions does Human Ultracell have?
It is harmless and safe; it has no side effects or risks if administered with other alternate treatments. Whereas it has zero toxicity, it does not produce any adverse reaction and can be administered with full peace of mind since it does not have any interaction with other drugs. 

Starting at what age should Human Ultracell be administered?
It is necessary to boost organ values with Human Ultracell (anti-ageing vaccine) in persons of both sexes starting at age 30, up to age 90, thereby boosting the user’s mental and body levels to maintain his/her youthful energy and vigour.  

How much does Human Ultracell cost?
If we think about purchasing life insurance, this only gives us peace of mind, since our family is protected, but we are not protecting our health or physical well-being in the years ahead.
If we could take out a policy which protected our health, would we? What price would you put on your health?

We should remember that the most important thing in life is not to simply survive, with diseases and chronic ailments, but to live it fully and with health.

Do insurance companies cover these treatments?
To date, no—only in the case of special arrangements.

CLINICAL INFORMATION AND PHARMACOLOGY

Total Formula, 1000 mg:
Composition, freeze-dried powder in 750-mg vial:
Contains 750 mg of freeze-dried powder, consisting of the following: 400 mg of whole unborn sheep fresh foetal tissue, 100 mg of umbilical cord stem cells and 250 mg comprising the following: Phosphatidyl serine, dihydrolipoic acid, propionyl arginate, riboflavin, thiamine, isonicotinate, huperizin, vinpocetin, pregnenolone, coenzyme Q10, Procaine KH3, DHEA, essential enzymes, glycine and mannitol. The extraction and processing of the tissues is done preserving their biological integrity. No additive is used.

Composition, solvent formula in 250-mg syringe: 
The solvent in the 3-ml syringe contains 250 mg of amino acids, L-glutamine, L-arginine, L-pyroglutamate, GABA, L-glycine, L-lysine, L-tyrosine, seleginile chlorhydrates, DMAE,  acetyl-L-carnitine, and stabilisers which serve to dilute the freeze-dried powder at the time of administering the injection IM deep in the buttocks region. The injection is painless.

Mechanism of Action:
Human Ultracell acts by means of several mechanisms, all of them inducers of the body’s natural functions. As regards its cell components, it acts by phagocytosis; it passes through to the extra-cellular fluid and subsequently to the intra-cellular fluid to commence the work of cell renewal, regeneration and building. On the other hand, its biostimulants and amino acids induce the body to increase production of HGH and other hormones of vital necessity for keeping the body and its functions youthful. This is followed by the catalytic action of enzymes and other components capable of regulating the body’s systems and organs, especially the circulatory and neuro-hormonal ones, as well as cognitive functions.  

Pharmacokinetics:
Human Ultracell:
The somatic cells contained in the injectable product, immediately after administration thereof, start to become activated, are absorbed quickly into the bloodstream, and the body starts the process of their degradation; in this stage, they are attacked by macrophages, whereby they go on to form a structural part of the extra-cellular fluid. At this point, a series of processes occurs, such as pinocytosis, osmosis, etc., and the cells head towards the intra-cellular fluid, where they will begin to exert a regenerative and repairing effect. As of week three or four after the administration of the treatment, up to 10 to 12 months afterwards, the regenerative processes take place, with visible cell renewal effects.

As regards amino acids, their exact ratio in the body depends on the type of proteins ingested, the corresponding synthesis at the cell level, and selective excretion by the kidneys.  Once they have penetrated the cells (by facilitated or active transport), the amino acids combine with one another by intra-cellular fermentation action and form proteins. Each cell has a protein storage limit, and the excess amino acids in the bloodstream are converted into new products at the hepatic level and used to release energy or else stored as fat.  Those which are not used are eliminated by the renal system. The enzymes present in the formula act as biocatalyzers of the innumerable metabolic reactions involved in cell function; together with vitamins and anti-oxidants, they favour the integrity of the membranes, as well as stimulating cell metabolism and regeneration of systems which make up the body.

Once absorbed, the enzymes are distributed systemically, acting especially wherever a disease produced by the deficiency of the same is located. This spot-targeting has its basis in the interaction with alpha-2 macroglobulin, a substance produced by activated immune cells (macrophages/monocytes). The cells which activate the immune system provide mainly and quickly the enzymes present in the proteinases. Consequently, in areas with immunologically active tissues, there is enriched proteolytic activity in the case of hydrolytic enzymes.

The synergetic action of Human Ultracell’s components induces and stimulates the release of human growth hormone, which provokes the growth of all body tissues capable of growing and stimulates increased cell volume, as well as mitosis, with the development of a higher number of cells and with a less defective genetic pattern.

Indications and Dosage:
Indications by Specialisation, Dose, Frequency and Administration of the Treatment.

General and Anti-ageing Medicine, Internal Medicine, Geriatrics, Plastic Surgery, and any other medical specialisation related or not to the aforementioned ones:

1. Ageing
2. Premature Ageing
3. Physical Asthenia
4. Chronic Diseases
5. Immune Deficiencies
6. Diminished Mental Faculties
7. Diminished Sexual Function
8. Oenological Processes.

With what frequency should the Human Ultracell treatment be administered?
To control the ageing process, “vaccination” once a year is recommended, with the following indications:
Biologically and clinically, it has been proven that ageing starts at age 28, when physiological changes slowly commence which result in physical and organ deterioration,  weakening and wearing down the body’s functions and facilitating diseases which sometimes present with no apparent symptoms. Healthy persons are prone to this as well; that is why we recommend that individuals of both sexes between the ages of 30 and 45 administer one (1) treatment each year, consisting of a box which contains 4 vials (750 mg each) and 4 syringes (250 mg each) of Human Ultracell, to be administered over 4 consecutive weeks (one injection per week) for a total of 1000 mg per application. This represents 4 I.U. during a month of treatment, until completing 4 injections.

For persons of both sexes between the ages of 46 and 60, when ageing due to organ and physical wear is greater and different pathologies have almost certainly already manifested themselves and others are developing, it is recommended to double the dose of Human Ultracell to stall the ageing process and avoid organ and physical wear from progressing. We recommend administering two (2) treatments a year, one each month for 2 consecutive months, comprising 2 boxes of 4 vials of 750 mg each (total of 8 vials) and 4 syringes of 250 mg each (total of 8 syringes). These should be administered over 8 consecutive weeks for a total of 1000 mg per week, representing 4 I.U. per month for a total of 8 I.U. in two months of treatment, until completing 8 injections.

For persons of both sexes age 61 and above, when evident biological ageing already exists, many organ values have been lost and there are clear deficiencies and shortages related to different pathologies, a more aggressive treatment is recommended of three (3) treatments a year, for 3 consecutive months, comprising 3 boxes of 4 vials of 750 mg each (12 vials) and 4 syringes of 250 mg each (total of 12 syringes). These should be administered over 12 consecutive weeks for a total of 1000 mg per dose administered, representing 4 I.U. per month for a total of 12 I.U. in three months of treatment, or until  completing 12 injections.

In all cases, once the injected treatment has finished, Human Citoplacell should be taken daily.

Analysis:
To control the ageing process annually, prevent degenerative diseases, decrease fatigue and stress, strengthen the osteo-articular system, increase libido, induce the release of human growth hormone, general organ regeneration through cell renewal, increased energy, as well as endurance for a greater number of physical activities.  

Contraindications:  When using the recommended doses, in no case have any adverse reactions been noted. However, Human Ultracell should not be administered within 30 days of having been vaccinated. Persons with diabetes must have it previously controlled, prior to administering Human Ultracell.

Side Effects: On some occasions, red aureoles can appear at the injection site (buttocks area), but the same disappear after 2 hours. Some cases have also been reported of slight headache due to the high cell content and protein load, wherefore it is recommended that, prior to administering Human Ultracell to more sensitive patients, the same should take 2 analgesic tablets or 2 Zymocell tablets.

Administration:  The solution to be injected is obtained by dissolving the freeze-dried formula contained in the vial with the solvent formula in the syringe, especially designed for that purpose.  Once prepared, the mix should be shaken lightly and allowed to dissolve for a period of 20 minutes prior to injecting it (the injection does not produce any pain or burning sensation). Substances such as neuroleptics, tranquilisers, sedatives, barbiturates and steroids, which affect metabolic cycles, can diminish the effect of Human Ultracell. Therefore it is recommended to suspend the use of same whilst administering Human Ultracell.

It is recommended that the patient rest after each injection and that the same avoid physical exercise for up to 24 hours afterwards, as well as alcohol consumption for 48 hours.

SUMMARY OF CLINICAL STUDY:
Prove the therapeutic efficacy of HUMAN ULTRACELL as a stand-alone therapy, according to the dosing guidelines (established according to age), versus placebo, in the symptoms referred by patients, such as reduction of general fatigue, improved libido, physical performance, stress resistance, quality of sleep, concentration and memory; for a period of seven months.

Design: Double-blind, multicentric, placebo-controlled trial of 780 patients of both sexes (495 males and 285 females).  One group of 281 subjects was treated with HUMAN ULTRACELL and the other group of 499 subjects was treated with a placebo.

REFERENCES
www.nuevaeconomia.com. El mundo, February 6, 2000/Number 19.
Endotelio Cienc. Vol. 1, N° 1-2000. Antonio Carlos Jaramillo T. Revista Panamericana de Endotelio.
http://www. enplenitud.com/paginaspersonales/luissteinberg/
Bioplanet-Mundo May 28, 2002

Clinical Study
Adams et al. (1996) conducted an open clinical study on 40 women between the ages of 34 and 60, who presented diffuse symptoms attributable to ageing-related or premature-ageing rheumatism. They were treated according to the following dosing guidelines for 24 weeks:  8 ampoules of Human Ultracell at a rate of 1 a week in combination with 1 ampoule of Rhemacell daily, throughout the treatment term.

Results: Adams et al. (1996) arrived at the conclusion that the reduction in intensity of the diffuse pain is significant during combined treatment with Human Ultracell and Rhemacell, favourably impacting mobility in 82% of the patients (Chart 1). In Chart 2, it is observed that after 6 months of treatment, 80% of the patients present no or slight pain, 15% moderate pain and 5% severe pain; this is directly related to the improved mobility obtained. During the clinical trial, no side effects were reported.  Treatment with Human Ultracell/Rhemacell was well-tolerated by the patients who took part in the clinical study. No episodes of acute pain were reported.

CHART 1. Improvement of Pain and Mobility during 6 Months of Treatment with Human Ultracell + Rhemacell.

CHART 2. Intensity of Pain in Patients with Improved Mobility during 6 Months of Treatment with Human Ultracell and Rhemacell.

Clinical Study:
2001-2005
A long-term open study (chart 1) was conducted of 119 females and 281 males, between the ages of 26 and 88, who suffered from certain disease-related problems and who were treated according to the yearly dosing guidelines established for Human Ultracell cell therapy.

In the researchers’ opinion, the following results and positive changes were noted and claimed by the patient, following the clinical check-up:

67% of the patients (268 subjects) reported significant improvement, translating to reduced use of medications, drastic decrease in doctor’s visits, hair growth, disappearance of skin spots, restful sleep, greater interest in usual environment,  greatly improved sociability,  increased sexual function and activity, better circulation (skin and extremities), improved skin elasticity, 20-30% greater corporal capacity (hours of work), less fatigue, notable improvement of irritability, absence of frequent eye disorders (dryness), and notable improvement of depression. 20% of the subjects (80 patients) under study reported moderate improvement of symptoms or problems considered to be a disease, and 13% (52 patients) did not observe any change in the referenced symptoms (Chart 1).

CHART 1.

Evaluation, by the doctor and the patients, of therapeutic activity of Human Ultracell following treatment of the referenced symptoms.